Allworth Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Allworth Financial’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$655K	Sell	26,462 -2,127	-7%	-$50.7K	﹤0.01%	849
2025 Q4	$667K	Sell	28,589 -706	-2%	-$15.7K	﹤0.01%	819
2025 Q3	$577K	Buy	29,295 +8,323	+40%	+$171K	﹤0.01%	839
2025 Q2	$455K	Buy	20,972 +20,705	+7,755%	+$489K	﹤0.01%	865
2025 Q1	$6.19K	Hold	267	–	–	﹤0.01%	2650
2024 Q4	$6.11K	Sell	267 -94	-26%	-$2.02K	﹤0.01%	2665
2024 Q3	$7.18K	Hold	361	–	–	﹤0.01%	2410
2024 Q2	$6.12K	Buy	361 +109	+43%	+$1.7K	﹤0.01%	2425
2024 Q1	$4.02K	Sell	252 -19	-7%	-$286	﹤0.01%	2498
2023 Q4	$4.56K	Buy	271 +246	+984%	+$3.36K	﹤0.01%	2308
2023 Q3	$293	Buy	+25	New	+$334	﹤0.01%	3175
2023 Q1	–	Sell	-68	Closed	-$1.26K	–	3210
2022 Q4	$1.26K	Buy	68 +4	+6%	+$62	﹤0.01%	2397
2022 Q3	$1K	Buy	+64	New	+$758	﹤0.01%	2345

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Allworth Financial's CPRX Position: Q1 2026 in Review

Allworth Financial reduced its Catalyst Pharmaceutical (CPRX) stake by 7.4% in Q1 2026, selling an estimated $50.7K and leaving 26,462 shares worth $655K. The position accounts for ﹤0.01% of the portfolio, ranked #849.

Allworth Financial first reported a position in CPRX in Q3 2022 and has held it in 13 quarters since. The position peaked at $667K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Allworth Financial held 26,462 shares of Catalyst Pharmaceutical worth $655K as of Q1 2026.
Allworth Financial sold 2,127 Catalyst Pharmaceutical shares in Q1 2026, an estimated $50.7K.
Catalyst Pharmaceutical made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #849 holding.
Allworth Financial first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 13 quarters since.
Allworth Financial's Catalyst Pharmaceutical position peaked at $667K in Q4 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.